Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
Journal
The Lancet Oncology
Journal Volume
22
Journal Issue
7
Pages
991-1001
Date Issued
2021
Author(s)
Galle P.R.
Finn R.S.
Qin S.
Ikeda M.
Zhu A.X.
Kim T.-Y.
Kudo M.
Breder V.
Merle P.
Kaseb A.
Li D.
Mulla S.
Verret W.
Xu D.-Z.
Hernandez S.
Ding B.
Liu J.
Huang C.
Lim H.Y.
Ducreux M.
Abstract
Background: Understanding patients' experience of cancer treatment is important. We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150
SDGs
Other Subjects
alpha fetoprotein; atezolizumab; bevacizumab; sorafenib; angiogenesis inhibitor; antineoplastic agent; atezolizumab; bevacizumab; monoclonal antibody; protein kinase inhibitor; sorafenib; abdominal swelling; adult; advanced cancer; Article; body image; ca
Publisher
Lancet Publishing Group
Type
journal article